- Home
- TARS vs HAYW Comparison
TARS vs HAYW Comparison
Compare TARS & HAYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | HAYW |
|---|---|---|
| Founded | 2016 | 1925 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TARS | HAYW |
|---|---|---|
| Price | $66.39 | $13.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $89.00 | $19.50 |
| AVG Volume (30 Days) | 403.1K | ★ 1.9M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | 25.93 |
| EPS | N/A | ★ 0.68 |
| Revenue | $451,360,000.00 | ★ $1,122,155,000.00 |
| Revenue This Year | $55.67 | $6.22 |
| Revenue Next Year | $30.64 | $5.96 |
| P/E Ratio | ★ N/A | $19.79 |
| Revenue Growth | ★ 146.71 | 6.71 |
| 52 Week Low | $38.51 | $11.10 |
| 52 Week High | $85.25 | $17.73 |
Technical Indicators
Market Signals| Indicator | TARS | HAYW |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 24.92 |
| Support Level | $65.62 | N/A |
| Resistance Level | $67.70 | $16.66 |
| Average True Range (ATR) | 2.75 | 0.38 |
| MACD | -0.44 | -0.05 |
| Stochastic Oscillator | 39.31 | 0.58 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2025.